du.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Reforming the Swedish pharmaceuticals market: Consequences for costs per defined daily dose
Mälardalens Högskola.
Umeå Universitet.
Högskolan Dalarna, Akademin Industri och samhälle, Nationalekonomi.
2016 (Engelska)Ingår i: International Journal of Health Economics and Management, ISSN 2199-9023, E-ISSN 2199-9031, Vol. 16, nr 3, s. 201-214Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

In 2009 and 2010, the Swedish pharmaceuticals market was reformed. One of the stated policy goals was to achieve low costs for pharmaceutical products dispensed in Sweden. We use price and sales data for off-patent brand-name and generic pharmaceuticals to estimate a log-linear regression model, allowing us to assess how the policy changes affected the cost per defined daily dose. The estimated effect is an 18 % cost reduction per defined daily dose at the retail level and a 34 % reduction in the prices at the wholesale level (pharmacies’ purchase prices). The empirical results suggest that the cost reductions were caused by the introduction of a price cap, an obligation to dispense the lowest-cost generic substitute available in the whole Swedish market, and the introduction of well-defined exchange groups. The reforms thus reduced the cost per defined daily dose for consumers while being advantageous also for the pharmacies, who saw their retail margins increase. However, pharmaceutical firms supplying off-patent pharmaceuticals experienced a clear reduction in the price received for their products.

Ort, förlag, år, upplaga, sidor
2016. Vol. 16, nr 3, s. 201-214
Nyckelord [en]
Pharmaceutical industry, National pharmacy monopoly, Pharmacy deregulation, Competition, Generics, Pricing
Nationell ämneskategori
Nationalekonomi
Forskningsämne
Komplexa system - mikrodataanalys
Identifikatorer
URN: urn:nbn:se:du-22584DOI: 10.1007/s10754-016-9186-4ISI: 000384910900001PubMedID: 27878673OAI: oai:DiVA.org:du-22584DiVA, id: diva2:946825
Tillgänglig från: 2016-07-06 Skapad: 2016-07-06 Senast uppdaterad: 2017-11-28Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Rudholm, Niklas
Av organisationen
Nationalekonomi
I samma tidskrift
International Journal of Health Economics and Management
Nationalekonomi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 275 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf